Next Article in Journal
Oxidative Stress Induced Mitochondrial Failure and Vascular Hypoperfusion as a Key Initiator for the Development of Alzheimer Disease
Next Article in Special Issue
Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE)
Previous Article in Journal
Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
Article Menu

Export Article

Commentary published on 10 June 2010, see Pharmaceuticals 2010, 3(6), 1887-1891.

Open AccessReview
Pharmaceuticals 2010, 3(1), 146-157; doi:10.3390/ph3010146

Impact of Glycosylation on Effector Functions of Therapeutic IgG

1,2,3,4
and
1,2,3,*
1
INSERM UMRS 872, Paris, F-75006 France
2
Cordeliers Research Center, Université Pierre & Marie Curie, UMRS 872, Paris, F-75006, France
3
Université Paris-Descartes, UMRS 872, Paris, F-75006 France
4
Laboratoire français du Fractionnement et des Biotechnologies (LFB), Les Ulis, France
Paper published on Special Issue “Monoclonal Antibody”, edited by Jagadeesh Bayry.
*
Author to whom correspondence should be addressed.
Received: 15 December 2009 / Revised: 30 December 2009 / Accepted: 8 January 2010 / Published: 12 January 2010
(This article belongs to the Special Issue Monoclonal Antibody)
View Full-Text   |   Download PDF [1675 KB, uploaded 13 January 2010]   |  

Abstract

Human IgG has only one conserved glycosylation site located in the Cγ2 domain of the Fc region that accounts for the presence of two sugar moieties per IgG. These IgG sugar cores play a critical role in a number of IgG effector functions. In the present review, we describe the main characteristics of IgG Fc glycosylation and some abnormalities of serum IgG glycosylation. We also discuss how glycosylation impacts on monoclonal antibodies (mAbs) and IVIg effector functions and how these molecules can be engineered. Several therapeutic antibodies have now been engineered to be no- or low-fucose antibodies and are currently tested in clinical trials. They exhibit an increased binding to activating FcγRIIIA and trigger a strong antibody-dependent cell cytotoxicity (ADCC) as compared to their highly-fucosylated counterparts. They represent a new generation of therapeutic antibodies that are likely to show a better clinical efficacy in patients, notably in cancer patients where cytotoxic antibodies are needed.
Keywords: antibody; Fc receptor; glycosylation; IgG antibody; Fc receptor; glycosylation; IgG
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Abès, R.; Teillaud, J.-L. Impact of Glycosylation on Effector Functions of Therapeutic IgG. Pharmaceuticals 2010, 3, 146-157.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top